VESIcare Side Effects
Generic Name: solifenacin
Note: This page contains side effects data for the generic drug solifenacin. It is possible that some of the dosage forms included below may not apply to the brand name VESIcare.
It is possible that some side effects of VESIcare may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to solifenacin: oral tablet
As well as its needed effects, solifenacin (the active ingredient contained in VESIcare) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking solifenacin, check with your doctor immediately:Less common
- Bladder pain
- bloody or cloudy urine
- decrease in the frequency of urination
- decrease in urine volume
- difficult, burning, or painful urination
- difficulty in passing urine (dribbling)
- frequent urge to urinate
- painful urination
- swelling of the lower legs
- unusual tiredness or weakness
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- chest pain or discomfort
- irregular heartbeat recurrent
- irregular or slow heart rate
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- rapid weight gain
- shortness of breath
- tingling of the hands or feet
- unusual weight gain or loss
Some solifenacin side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:Less common
- Acid or sour stomach
- body aches or pain
- feeling sad or empty
- general feeling of discomfort or illness
- joint pain
- lack of appetite
- loss of interest or pleasure
- lower back or side pain
- muscle aches and pains
- pounding in the ears
- runny nose
- slow or fast heartbeat
- sore throat
- stomach discomfort, upset, or pain
- tender, swollen glands in the neck
- trouble concentrating
- trouble with sleeping
- trouble with swallowing
- upper abdominal or stomach pain
- voice changes
- Hives or welts
- redness of the skin
- skin rash
For Healthcare Professionals
Applies to solifenacin: oral tablet
Gastrointestinal side effects have been reported the most frequently. These have included dry mouth (7.7% to 27.6%) and constipation (3.7% to 13.4%). Dyspepsia (1.4% to 3.9%), nausea (1.7% to 3.3%), abdominal pain (upper) (1.2% to 1.9%), and vomiting (0.2% to 1.1%) have also been reported. Gastrointestinal side effects reported postmarketing have included decreased appetite, gastroesophageal reflux disease, and ileus.
Respiratory side effects have included cough (0.2% to 1.1%). Respiratory side effects reported postmarketing have included dysphonia.
Psychiatric side effects have included depression (0.8% to 1.2%). Confusion and hallucinations have been reported during postmarketing experience.
Ocular side effects have included blurred vision (3.8% to 5.9%) and dry eyes (0.3 to 1.6%). Anticholinergic side effects including fixed and dilated pupils have been reported in patients with chronic use of or at doses higher than the maximum recommended dose. Ocular side effects reported postmarketing have included glaucoma.
Nervous system side effects have included dizziness (1.8% to 1.9%) and tremors. Headache, confusion, hallucinations, somnolence, and delirium have been reported during postmarketing experience.
Genitourinary side effects have included urinary tract infections (2.8% to 4.8%) and urinary retention (1.4%).
In general, the most frequently reported side effects have included dry mouth and constipation and the incidence of these side effects was higher in 10 mg compared to 5 mg dose group. In a four 12-week double-blind clinical trial, there were three intestinal serious side effects in patients, all treated with 10 mg. The overall rate of serious side effects was 2%. Compared to twelve weeks of therapy, the incidence and severity of side effects were similar in patients who remained on therapy for up to 12 months. The most frequent reason for discontinuation due to a side effect was dry mouth (1.5%).
A cardiac electrophysiologic study evaluating the QT interval at the time of peak plasma concentrations, following 10 and 30 mg solifenacin (the active ingredient contained in VESIcare) doses, has reported a QT prolongation effect. The effect appeared greater with the highest solifenacin dosage, although the effect did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
Cardiovascular side effects have included hypertension (0.5% to 1.4%). A prolonged QT interval effect has been reported during cardiac electrophysiologic studies. Torsades de Pointes have been reported during postmarketing experience. Other cardiovascular side effects reported postmarketing include atrial fibrillation, tachycardia and palpitations.
Dermatologic side effects have included dry skin and postmarketing reports of exfoliative dermatitis and erythema multiforme.
Immunologic side effects have included infections. These have included influenza (0.9% to 2.2%) and pharyngitis (0.3% to 1.1%).
Metabolic side effects have included heat prostration with the use of anticholinergic drugs, similar to solifenacin (the active ingredient contained in VESIcare) in hot environments. Metabolic side effects reported postmarketing have included hyperkalemia.
Hypersensitivity side effects including angioedema, rash, pruritus, and urticaria have been reported during postmarketing experience.
Other side effects have included fatigue (1% to 2.1%) and edema of the lower limbs (0.3% to 1.1%).
Renal side effects reported postmarketing have included renal impairment.
Hepatic side effects reported postmarketing have included liver disorders mostly characterized by abnormal liver function tests (AST, ALT, and GGT).
Musculoskeletal and connective tissue side effects reported postmarketing have included muscular weakness.
More about VESIcare (solifenacin)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.